louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06937021: The Impact of an Art and Philosophy-based Intervention on Children's Eco-anxiety
Official title: The Impact of an Art and Philosophy-based Intervention on Children's Eco-anxiety: A Pilot Study
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Eco-anxiety
Psychological Distress
Tolerance to Distress
Hope
Mental Health
Keywords: Art-based interventions
Philosophical inquiry
eco-anxiety
children
schools
mental health
Lead sponsor: Bishop's University
Sponsor class: OTHER
Collaborators: name: Social Sciences and Humanities Research Council of Canada
First posted: 2025-04-20
Enrollment: 1000
Sex: ALL
Minimum age (years): 5
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Objective: To examine the impact of climate change on children's mental health by comparing the effectiveness of an arts only intervention (ABI) and an arts and philosophy-based intervention (APBI) on children's eco-anxiety, tolerance to distress and hope for the future in school settings. The investigators hypothesized that the children assigned to the combined arts and philosophy intervention would show reductions in self-reported eco-anxiety, as well as increases in tolerance to distress and hope for the future in the context of climate change, when compared to children assigned to the arts-only intervention.

Setting: This study is conducted in public primary schools from England. Participants: Participants are students in grades 3 to 6. Main Outcomes and Measures: The primary outcome is self-reported eco-anxiety scores. Secondary outcomes are self-reported tolerance to distress, hope for the future and mental health (depression and anxiety symptoms).


Eligibility criteria: Inclusion Criteria:

* being an elementary school student

Exclusion Criteria:

* not being an elementary school student

Primary outcomes:
measure: Eco-anxiety
timeFrame: From enrollment to the end of treatment at 8 weeks
Secondary outcomes:
measure: Tolerance to distress
timeFrame: From enrollment to the end of treatment at 8 weeks
measure: Hope
timeFrame: From enrollment to the end of treatment at 8 weeks
measure: Mental health
timeFrame: From enrollment to the end of treatment at 8 weeks
Other outcomes:
Locations:
city: Henhurst Ridge
country: United Kingdom
facility: Reach2 Academy, NorthStar Academy
state: Burton-on-Trent
Study officials:
affiliation: Bishop's University
name: Catherine Malboeuf-Hurtubise, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00850421: Pilot Study of BOTOX for Migraine Headaches
Official title: A Single-Center Pharmacoeconomic Pilot Study of BOTOX® (Botulinum Toxin Type A) for the Prophylactic Treatment of Migraine Headaches
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Migraine Headache
Keywords: migraine headache
Botulinum Toxin Type A
BOTOX
BTX-A
Lead sponsor: HealthPartners Institute
Sponsor class: OTHER
Collaborators: name: Allergan
First posted: 2009-02-25
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purposes of this study are to assess whether subjects treated with BOTOX will:

1. have a decrease in the frequency and intensity of migraine headaches
2. experience improvements in quality of life
3. experience a reduction in the frequency of health care services obtained.


Eligibility criteria: Inclusion Criteria:

* Subjects \> 18 years of age
* Subject has an established history of migraine headache, with or without aura, per IHS criteria (1.2.1 or 1.1), for at least 6 months prior to screening.
* Subject receives primary health care from Park Nicollet Health Services.

Exclusion Criteria:

* Subject has received previous injections of botulinum toxin of any serotype for any reason, within the 6 months prior to study participation.

Additional eligibility will be discussed at point of contact

Primary outcomes:
measure: To Determine Whether Resource Utilization is Decreased in Subjects Treated With BOTOX Injections for Episodic Migraine Headache.
timeFrame: 190 days
Secondary outcomes:
measure: To Determine Whether Quality of Life is Improved in Subjects Treated With BOTOX Injections for Episodic Migraine Headache.
timeFrame: 190 days
measure: To Assess the Effect of BOTX Injections on the Frequency and Intensity of Migraine Episodes in Subjects With Episodic Migraine Headache.
timeFrame: 190 days
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: Park Nicollet Health Services
state: Minnesota
Study officials:
affiliation: Park Nicollet Health Services
name: Frederick Taylor, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03588221: Simplifying the World Health Organization (WHO) Protocol for Hand Hygiene
Official title: Simplifying the WHO Protocol for Hand Hygiene: Three Steps and 15 Seconds - a Randomized Cross-over Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hand Hygiene
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2018-07-17
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Randomized crossover trial, comparing the following four sets of hand hygiene measurements per participant:

1. Six-step hand hygiene technique with an application time of 30 seconds
2. Six-step hand hygiene technique with an application time of 15 seconds
3. Three-step hand hygiene technique with an application time of 30 seconds
4. Three-step hand hygiene technique with an application time of 15 seconds
Primary purpose: SCREENING

Brief summary: Non-inferiority in terms of reduction of bacterial counts will be investigated when combining the simpler three-step hand hygiene technique for the use of hand rub with a shorter application time of 15 seconds compared to the to the three steps technique with an application time of 30 seconds and the technique consisting in six steps.


Eligibility criteria: Inclusion Criteria:

* Adult participants (≥18 years)

Exclusion Criteria:

* skin disorders as determined by a dermatologist
* inability to follow procedures
* insufficient knowledge of the project language
* inability to give informed consent

Primary outcomes:
measure: Change of bacterial counts on hands pre and post hand hygiene measure
timeFrame: 30 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: Division of Infectious Diseases and Hospital Epidemiology
Study officials:
affiliation: University Hospital Basel, CH-4031 Basel
name: Sarah Tschudin Sutter, PD MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04110821: Quality of Life After Conservative and Surgical Treatment of Pelvic Organ Prolapse
Official title: Quality of Life After Conservative and Surgical Treatment of Pelvic Organ
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Pelvic Organ Prolapse
Quality of Life
Incontinence
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2019-10-01
Enrollment: 134
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: In this study all patients with POP being treated at the study site are subject to inclusion. This concerns patients with different symptoms of POP such as urine or fecal incontinence, chronic obstipation, dysfunction of the bowel evacuation, micturition disorder, chronic pelvic pain, complaints associated to pelvic floor descent and pelvic organ prolapse. They also may have combinations of these symptoms.

Brief summary: This is an observational study that gives baseline and follow-up information, that does not directly influence the allocation of patients to various treatment Options (conservative and surgical therapy of Pelvic Organ Prolapse) but the knowledge gained of the data will help to develop treatment strategies.


Eligibility criteria: Inclusion Criteria:

- Pelvic Organ Prolapse (POP)

Exclusion Criteria:

* \< 18 years
* Patients unable to understand an informed consent
* Patients unwilling to participate
* emergency operations
* pregnancy
* Overactive Bladder without descensus
* Stool incontinence without POP

Primary outcomes:
measure: symptom change assessed by German Pelvic Floor Questionnaire (GPFQ)
timeFrame: before therapy and up to 5 years post-therapy
Secondary outcomes:
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: University Hospital Basel/Dep. of Visceral Surgery (Clarunis)
Study officials:
affiliation: University Hospital Basel, Clarunis
name: Daniel Steinemann, PD Dr. med.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00725621: Real Life Dosing of Remicade for Rheumatoid Arthritis in Austria Monitored Over 9 Infusions (Study P03756)(COMPLETED)
Official title: Real Life Dosing Regimen of Remicade in Austria, Monitored Over 9 Consecutive Infusions in Rheumatoid Arthritis Therapy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rheumatoid Arthritis
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
Collaborators: name: Centocor, Inc.
First posted: 2008-07-30
Enrollment: 516
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with severe RA being treated at specialized centers.

Brief summary: This is a prospective, open-label, 1-arm, multicenter observational study to determine the average Remicade dosage and time span between 9 infusions in subjects with rheumatoid arthritis (RA)

Detailed description: This study population was chosen from a non-probability sample.

Eligibility criteria: Inclusion Criteria:

* Severe RA (indication according to Austrian labeling).

Exclusion Criteria:

* According to Summary of Product Characteristics (SPC).

Primary outcomes:
measure: Mean Time Interval Between Remicade Infusions in Participants During Maintenance Treatment Following Induction Therapy
timeFrame: Maximum of 16 weeks
measure: Median Time Interval Between Remicade Infusions in Participants During Maintenance Treatment Following Induction Therapy
timeFrame: Maximum of 16 weeks
measure: Mean Dose of Remicade in Participants Receiving Induction Therapy and Subsequent Maintenance Therapy
timeFrame: Maximum of 102 weeks
measure: Median Dose of Remicade in Participants Receiving Induction Therapy and Subsequent Maintenance Therapy
timeFrame: Maximum of 102 weeks
measure: Mean Remicade Dose Per Participant
timeFrame: Maximum of 102 weeks
measure: Median Remicade Dose Per Participant
timeFrame: Maximum of 102 weeks
Secondary outcomes:
measure: Disease Progression Specified by the Time Period Between Onset of Rheumatoid Arthritis (RA) and Onset of Remicade Therapy
timeFrame: 24 months maximum
measure: Number and Kind of Previous Therapies With Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
timeFrame: 24 months maximum
measure: Impact of Remicade Location (Specialized Hospitals Versus Extramural Infusion Centers) on the Physical Component Summary Score (PCS)
timeFrame: 24 months maximum
measure: Impact of Remicade Location (Specialized Hospitals Versus Extramural Infusion Centers) on the MCS
timeFrame: 24 months maximum
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03615521: Different Proprioceptive Neuromuscular Facilitation (PNF) Technique in Patients With Knee Osteoarthritis
Official title: Diz Osteoartritinde Farklı Proprioseptif Nöromüsküler Fasilitasyon Tekniklerinin, Ağrı, Propriosepsiyon, Postural Kontrol, Kas Kuvveti, Eklem Hareket Açıklığı ve Diz Fonksiyonları Üzerine Olan Etkileri
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Muscle Weakness
Balance Disorders
Knee Pain
Knee Osteoarthritis
Lead sponsor: Karamanoğlu Mehmetbey University
Sponsor class: OTHER
First posted: 2018-08-06
Enrollment: 35
Sex: ALL
Minimum age (years): 45
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The aim of this study is to investigate the effects of 6-week physiotherapy and rehabilitation programs involving different 'Proprioceptive Neuromuscular Facilitation' (PNF) techniques in patients with knee osteoarthritis on pain, proprioception, postural control, muscle strength, range of motion and knee functions

Detailed description: The results obtained from this study will contribute to the selection of PNF technique which is most suitable for physiotherapies working on knee osteoarthritis in clinics as well as demonstrating the efficacy of PNF which has been studied in the literature very few times.

As a result of this study, the evidence value of the PNF technique will be determined in the physiotherapy and rehabilitation program of patients with knee osteoarthritis, and the efficacy of this technique, which is theoretically adopted, will be demonstrated scientifically. It will also determine the most ideal of the two PNF techniques to be applied in patients with knee osteoarthritis

Eligibility criteria: Inclusion Criteria:

* Between the ages of 45-65
* The diagnosis of stage 1-2 osteoarthritis by the orthopedist
* Volunteerig for research
* No hearing, vision and speech impediment

Exclusion Criteria:

* Patients with intra-articular contracture,
* No Meniscus and no ligament problems
* Presence of any neurological or cardiopulmonary disease that may affect the results of the study

Primary outcomes:
measure: Quadriceps Femoris Muscle Strength
timeFrame: 6 week
Secondary outcomes:
measure: Knee Proprioception (30-45 and 60 degree)
timeFrame: 6 week
measure: KOOS score
timeFrame: 6 week
measure: Step test
timeFrame: 6 week
measure: Womac Score
timeFrame: 6 week
measure: 6 Minute walking test
timeFrame: 6 week
measure: Balance
timeFrame: 6 week
measure: Knee Pain Severity
timeFrame: 6 week
measure: Algometer
timeFrame: 6 week
Other outcomes:
measure: Time up and go test
timeFrame: 6 week
Locations:
city: Ankara
country: Turkey
facility: Hacettepe
Study officials:
affiliation: Hacettepe University
name: Filiz Can, Prof.
role: STUDY_DIRECTOR
References:
Clinical trial NCT04447521: Surveillance of Non-invasive Streptococcus Pneumoniae Infections in Belgium
Official title: A 20-months Surveillance of Non-invasive Streptococcus Pneumoniae Infections in Belgium to Evaluate National Vaccination Strategy
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Pneumonia
Otitis Media
Sinusitis Bacterial
Lead sponsor: Sciensano
Sponsor class: OTHER_GOV
Collaborators: name: Pfizer
name: Merck Sharp & Dohme LLC
name: Universitaire Ziekenhuizen KU Leuven
First posted: 2020-06-25
Enrollment: 3600
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients suffering from non-invasive pneumococcal disease (diagnosed as CAP, sinusitis and otitits media) and living in Belgium at the time of the study.

Brief summary: The investigators will conduct a prospective observational study of non-invasive S. pneumoniae infections in Belgium and characterize serotype distributions to evaluate national vaccination programs.

Detailed description: The investigators will conduct a surveillance of non-invasive S. pneumoniae infections in Belgium (September 2020-May 2025). Monthly, 12 peripheral hospitals will send the first 15 unduplicated clinical S. pneumoniae samples (coming from patients diagnosed with pneumonia, otitits media or sinusitis) to the investigators. The investigators will determine the serotype and the antibiotic resistance profile of these clinical isolates. Whole genome sequencing will be performed on a subset of these isolates.

From May 2021, 13 extra participating centers have been added to the study.

Eligibility criteria: Inclusion Criteria:

* Patients living in Belgium at the time of the study,
* from whom unduplicated S. pneumoniae isolates were collected in routine practices,
* from non-invasive upper (e.g.: pus/fluid from nasal sinus or from otitis media fluid) or lower respiratory tract (e.g. sputum bronchial or endotracheal aspirate, bronchoalveolar fluid (BAL),...) clinical samples,
* from patients diagnosed with pneumonia, sinusitis and otitis.

Exclusion Criteria:

• Patients for whom S. pneumoniae was simultaneously isolated from blood or another usually sterile specimen

Primary outcomes:
measure: Establish insight in serotype dynamics for non-invasive pneumococcal diseases in Belgium prospectively, in association with changing vaccination programs (campaigns).
timeFrame: September 2020-May 2025
Secondary outcomes:
measure: Surveillance of emerging serotypes, clones and drug resistances. Study of the genetic divergences between invasive and non-invasive pneumococcal diseases isolates.
timeFrame: September 2020-May 2025
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Sciensano
Study officials:
affiliation: Sciensano
name: Pieter-Jan Ceyssens, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00144521: Comparative Study (Double-Blind) of MRA for Rheumatoid Arthritis (RA)
Official title: A Double-Blind, Phase III Study to Evaluate the Efficacy and Safety of MRA in Patients With RA
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Rheumatoid Arthritis
Lead sponsor: Chugai Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2005-09-05
Enrollment: 127
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the clinical efficacy and safety of MRA in a double-blind, parallel-group, controlled study using MRA or methotrexate (MTX) in rheumatoid arthritis (RA) patients with MTX administered.


Eligibility criteria: Inclusion criteria

* Diagnosis of RA based on the 1987 classification criteria of the American College of Rheumatology (ACR)
* Disease duration of 6 months or more
* Treated with 8 mg/week of MTX for at least 8 weeks immediately preceding enrollment, and continued on this treatment up to initiation of the study drug
* Active disease at enrollment (less than 2 weeks before initiating treatment with a study drug), Which is defined as having at least 6 tender and 6 swollen joints among 49 and 46 joints stipulated by the Japanese Rheumatism Foundation's Drug Evaluation Committee and ESR at least 30 mm/hr and CRP not less than 1.0 mg/dL

Exclusion criteria

* Assessed as having Class IV Steinbrocker functional activity in the 4 weeks preceding treatment with the study drug
* Treated with infliximab, etanercept or leflunomide in the 12 weeks preceding treatment with the study drug
* Received any of the following therapies in the 2 weeks preceding initiation of treatment with the study drug.

  1. Administration of any DMARD or immunosuppressant other than MTX
  2. Administration of corticosteroids exceeding 10 mg/day as prednisolone
  3. Dose escalation or initiation of corticosteroids
* Received any of the following therapies in the 4 weeks preceding treatment with the study drug

  1. Plasma exchange therapy
  2. Surgical treatment (operation, etc.)

Primary outcomes:
measure: Frequency of ACR 20% improvement
timeFrame: week 24
Secondary outcomes:
measure: Frequency and severity of adverse events and adverse drug reactions
timeFrame: throughout study
measure: Time course of DAS28
timeFrame: throughout study
measure: time course of the frequency of ACR 20%, 50% and 70%
timeFrame: throughout study
Other outcomes:
Locations:
Study officials:
affiliation: Chugai Pharmaceutical
name: Takahiro Kakehi
role: STUDY_DIRECTOR
References:
Clinical trial NCT05790421: Effect of Foot Muscle Energy Technique in Patients With Diabetic Neuropathy
Official title: Effect of Foot Muscle Energy Technique in Patients With Diabetic Neuropathy: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetic Neuropathies
Keywords: Diabetic neuropathy
Foot muscle energy technique
Isometric muscle strength
Motor nerve conduction velocity study
Lead sponsor: October 6 University
Sponsor class: OTHER
First posted: 2023-03-30
Enrollment: 44
Sex: ALL
Minimum age (years): 40
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: Foot muscle energy technique and conventional physical therapy program administered in patients with type 2 Diabetic Neuropathy.

Detailed description: Foot muscle energy technique and conventional physical therapy program administered in patients with type 2 Diabetic Neuropathy.

Eligibility criteria: Inclusion Criteria:

* Participants (males and females) examined with non-insulin-dependent diabetes for ≥10 years determined by neurophysiological measurements were enrolled.
* The participants regularly took their diabetes medications during the assessment and treatment period.
* The use of any sedatives or anticonvulsants was contraindicated for all participants.

Exclusion Criteria:

• Uncontrolled non-insulin dependent diabetes and diagnosed for \< 10 years, neural, muscular, and skeletal system deformities; radiculopathy; and psychiatric disorders.

Primary outcomes:
measure: Motor nerve conduction study
timeFrame: 4 weeks
measure: Toe Strength Dynamometer
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: El-Sheikh Zayed City
country: Egypt
facility: October 6 University
state: Giza
Study officials:
References: